HBIO HARVARD BIOSCIENCE INC
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1123494 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.3%
TTM net income YoY78.1%
TTM EPS YoY173.1%
Revenue 3-yr CAGR-7.4%
Net income 3-yr CAGR—
Margins
Gross margin57.4%
Operating margin-1.8%
Net margin-13.2%
FCF margin-3.5%
EBITDA margin0.3%
Returns
ROE-123.1%
ROA-15.4%
ROIC (approx.)-3.2%
Asset turnover1.17x
Leverage & solvency
Liabilities / assets93.2%
Debt / equity7.28x
Current ratio1.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.06x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $22.20M | $22.73M | $20.75M | $23.73M | $20.59M | $20.45M | $21.77M | $24.56M |
| Cost of revenue | $9.89M | $10.10M | $8.51M | $9.56M | $8.57M | $8.92M | $9.59M | $10.54M |
| Gross profit | $12.31M | $12.63M | $12.24M | $14.17M | $12.02M | $11.53M | $12.18M | $14.01M |
| R&D expense | $2.26M | $2.45M | $2.33M | $2.18M | $2.13M | $2.19M | $2.32M | $2.33M |
| SG&A expense | $4.76M | $4.62M | $4.70M | $4.12M | $4.18M | $4.26M | $5.18M | $4.80M |
| Operating income | -$1.15M | -$978,000 | -$1.17M | $1.71M | $197,000 | -$819,000 | -$49.67M | $11,000 |
| Interest expense | $1.30M | $1.30M | — | $1.00M | $1.00M | $800,000 | — | — |
| Pretax income | -$2.69M | -$2.90M | -$3.31M | -$3.20M | -$1.13M | -$2.25M | -$50.79M | $590,000 |
| Income tax | -$72,000 | $14,000 | $117,000 | -$357,000 | $97,000 | $28,000 | -$454,000 | $572,000 |
| Net income | -$2.62M | -$2.91M | -$3.42M | -$2.85M | -$1.23M | -$2.28M | -$50.34M | $18,000 |
| EBITDA | -$650,000 | -$511,000 | -$731,000 | $2.17M | $622,000 | -$408,000 | -$49.22M | $470,000 |
| EPS (basic) | -0.58 | -0.64 | -0.77 | — | -0.28 | -0.52 | -11.42 | — |
| EPS (diluted) | -0.58 | -0.64 | -0.77 | — | -0.28 | -0.52 | -11.42 | — |
| Weighted avg. shares (diluted) | 4.56M | 4.53M | 4.47M | — | 4.46M | 4.43M | 4.41M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.86M | $6.50M | $7.10M | $8.61M | $6.82M | $7.44M | $5.55M | $4.11M |
| Receivables | $14.91M | $14.50M | $14.57M | $16.04M | $12.11M | $11.94M | $13.48M | $14.87M |
| Inventory | $23.49M | $22.23M | $22.20M | $20.80M | $21.60M | $22.25M | $22.82M | $23.25M |
| Current assets | $45.98M | $46.46M | $47.48M | $48.23M | $43.80M | $44.97M | $44.90M | $45.12M |
| PP&E, net | $5.40M | $5.35M | $4.87M | $4.79M | $4.99M | $4.91M | $5.01M | $5.11M |
| Goodwill | $9.30M | $9.33M | $9.37M | $9.56M | $9.53M | $10.15M | $8.96M | $56.32M |
| Intangibles | $6.18M | $6.22M | $6.91M | $7.64M | $8.38M | $9.14M | $10.13M | $11.13M |
| Total assets | $75.30M | $76.29M | $77.94M | $80.07M | $77.99M | $80.09M | $79.80M | $126.64M |
| Current liabilities | $26.13M | $24.79M | $23.86M | $21.96M | $54.40M | $55.20M | $55.60M | $54.96M |
| Short-term debt | $0 | $0 | $0 | $0 | — | — | — | $36.96M |
| Long-term debt | $37.15M | $36.68M | $36.21M | $35.87M | $33.97M | $34.90M | $36.40M | $0 |
| Total debt | $37.15M | $36.68M | $36.21M | $35.87M | $33.97M | $34.90M | $36.40M | $36.96M |
| Total liabilities | $70.19M | $68.87M | $67.89M | $66.34M | $63.92M | $64.36M | $64.97M | $63.30M |
| Shareholders' equity | $5.11M | $7.42M | $10.05M | $13.73M | $14.07M | $15.73M | $14.84M | $63.34M |
| Net debt | $32.30M | $30.18M | $29.11M | $27.26M | $27.15M | $27.46M | $30.85M | $32.85M |
| Shares outstanding | 4.57M | 4.55M | 4.51M | 4.47M | 44.58M | 44.53M | 44.21M | 44.07M |
| Cash flow statement | ||||||||
| Operating cash flow | -$248,000 | $325,000 | -$662,000 | -$96,000 | $1.08M | $2.75M | $2.99M | $1.73M |
| Capital expenditure | $927,000 | $688,000 | $426,000 | $449,000 | $207,000 | $89,000 | $513,000 | $301,000 |
| Free cash flow | -$1.18M | -$363,000 | -$1.09M | -$545,000 | $877,000 | $2.67M | $2.47M | $1.42M |
| Investing cash flow | -$1.34M | -$916,000 | -$620,000 | -$599,000 | -$348,000 | -$233,000 | -$683,000 | -$466,000 |
| Financing cash flow | -$45,000 | -$38,000 | -$9,000 | $2.45M | -$1.28M | -$1.26M | -$1.20M | -$1.36M |
| Depreciation & amortization | $500,000 | $467,000 | $443,000 | $456,000 | $425,000 | $411,000 | $451,000 | $459,000 |
| Stock-based compensation | $436,000 | $380,000 | $257,000 | $459,000 | $324,000 | $472,000 | $600,000 | $961,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.